Access to the PDF text

Archives of cardiovascular diseases
Volume 110, n° 12
pages 643-645 (décembre 2017)
Doi : 10.1016/j.acvd.2017.08.001
Received : 23 August 2017 ;  accepted : 29 August 2017
Targeting the immune response in atherosclerosis: It's time for clinical trials!
L’immunité innée comme cible thérapeutique dans l’athérosclérose : l’heure des essais cliniques !

Figure 1

Figure 1 : 

Immunomodulation of atherosclerosis. Cytokines produced by macrophages, endothelial cells and smooth muscle cells promote local chronic low grade inflammation, leading to atherosclerotic plaque growth and rupture. Neutralizing proinflammatory cytokines or immune cell deactivation through triggering receptor expressed on myeloid (TREM)-1 blockade are promising therapeutic approaches for cardiovascular diseases. IL: interleukin; LDL: low-density lipoprotein; TNF: tumour necrosis factor.

EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline